1. Introduction {#sec1-ncrna-03-00002}
===============

The last decade witnessed the discovery of an enormous number of tRNA-derived small RNAs (tDRs) in almost all branches of life \[[@B1-ncrna-03-00002],[@B2-ncrna-03-00002],[@B3-ncrna-03-00002],[@B4-ncrna-03-00002],[@B5-ncrna-03-00002],[@B6-ncrna-03-00002],[@B7-ncrna-03-00002],[@B8-ncrna-03-00002],[@B9-ncrna-03-00002],[@B10-ncrna-03-00002],[@B11-ncrna-03-00002],[@B12-ncrna-03-00002]\]. It has been suggested that these tDRs are not products of the random degradation of transfer RNAs (tRNAs), but are generated by precise processes. Accumulating experimental evidence suggests that they have important regulatory roles in translation, viral infections and tumor development \[[@B13-ncrna-03-00002],[@B14-ncrna-03-00002],[@B15-ncrna-03-00002],[@B16-ncrna-03-00002],[@B17-ncrna-03-00002],[@B18-ncrna-03-00002]\].

tDRs are classified as tRNA halves and tRNA-derived small RNA fragments (tRFs). tRNA halves are generated by a single cleavage at the anticodon of mature tRNAs, and their lengths range from 30 nt to 35 nt \[[@B1-ncrna-03-00002]\]. The biogenesis of tRNA halves is mostly induced by stress, such as oxidative stress \[[@B1-ncrna-03-00002]\]. tRFs, however, are generated from both precursor (pre-tRNAs) and mature tRNAs through Dicer-dependent or -independent processes, and are approximately 20 nt in size. However, this classification of tDRs is not definite. The features used to classify tRNA halves and tDRs are not unambiguous, and their functions and mechanisms overlap.

Early studies investigated tDRs individually and revealed that they are highly expressed in cells \[[@B19-ncrna-03-00002]\]. Recently, deep sequencing tools have been developed to comprehensively detect tDRs in silico \[[@B20-ncrna-03-00002]\]. The discovery of tDRs has raised the need for the storage and management of massive amounts of tDR data. Recent tDR identification tools and databases are mostly designed for eukaryotic cells. Consequently, in this review, we focus only on eukaryotic tDRs, and discuss the computational approaches and tools for identifying and managing the data for eukaryotic tDRs.

2. tDRs {#sec2-ncrna-03-00002}
=======

In eukaryotic cells, tRNA genes are transcribed by RNA polymerase III, and the resulting products (precursor tRNAs or pre-tRNAs) undergo further processing before maturation (mature tRNAs). These processes remove the 5' end (5' leader, by RNase P) and the 3' end (3' trailer, by RNase Z) of pre-tRNAs and then add the 5'-CCA-3' (CCA) trinucleotide to the 3' end of the tRNAs after cleavage. The splicing of tRNA transcripts and the extensive chemical modification to generate non-canonical bases also occur with these processes \[[@B21-ncrna-03-00002],[@B22-ncrna-03-00002],[@B23-ncrna-03-00002]\].

tDRs can be roughly classified as tRNA halves and tRFs. tRNA halves are formed by cleavage at the anticodon of mature tRNAs. Rny1p, a member of the RNase T2 family, and angiogenin, a member of the RNase A superfamily, are responsible for the cleavage to produce tRNA halves in yeast and mammalian cells, respectively \[[@B13-ncrna-03-00002],[@B24-ncrna-03-00002],[@B25-ncrna-03-00002]\]. Rny1p and angiogenin possess little substrate specificity. Rny1p is contained within the vacuole of the yeast cells and is released into the cytoplasm during stress-induced situations \[[@B26-ncrna-03-00002],[@B27-ncrna-03-00002]\]. Angiogenin is secreted and endocytosed into the cytoplasm \[[@B28-ncrna-03-00002]\]. Typically, these enzymes are inhibited, and stress induces their release from the inhibitors \[[@B29-ncrna-03-00002]\].

Two groups of tRNA halves have been discovered, namely 5' halves and 3' halves \[[@B29-ncrna-03-00002]\]. Besides, sex hormone-dependent tRNA-derived RNAs (SHOT-RNAs) were found to be constitutively expressed in human breast and prostate cancers \[[@B17-ncrna-03-00002]\]. They were considered tRNA halves, share counterparts of 5' and 3' halves, and possess biogenesis factors similar to those of tRNA halves. However, the expression of SHOT-RNAs is induced by sex hormones, and they are generated from tRNA species different from those of tRNA halves \[[@B17-ncrna-03-00002]\]. Diverse functional mechanisms of tRNA halves were suggested. It has been shown that endogenous 5' tRNA halves inhibit translation through the displacement of elF4G/A (eukaryotic translation initiation factors) from the mRNA transcripts \[[@B13-ncrna-03-00002],[@B30-ncrna-03-00002]\]. Thompson and Parker proposed four possible functional models of tRNA halves: the inhibition of translation through nicked tRNAs, the formation of a repression complex with other unknown proteins, guiding the inhibition of translation through their association with Argonaute or Piwi, and guiding the cleavage of mRNAs via their interaction with the tRNA processing enzymes RNase Z or RNase P \[[@B29-ncrna-03-00002]\].

tRFs, however, are produced from pre-tRNAs as well as mature tRNAs. Up until now, four types of tRFs have been identified and characterized by their provenance on tRNAs: tRF-1s, tRF-5s, tRF-3s, and i-tRFs. tRF-1s result from the cleavage of 3' trailer fragments of precursor tRNAs by RNases, including Dicer and RNase Z \[[@B11-ncrna-03-00002],[@B19-ncrna-03-00002],[@B31-ncrna-03-00002]\], and they usually begin exactly after the 3'-ends of mature tRNAs (5'-CCA-3' tails excluded) and possess poly-Us at their 3'-ends \[[@B19-ncrna-03-00002]\]. tRF-5s are generated by cleavage in the D-loop of tRNAs by Dicer, oftentimes with adenine as their 3'-ends \[[@B19-ncrna-03-00002],[@B31-ncrna-03-00002]\]. tRF-3s result from cleavage in the T-loop by Dicer, angiogenin and other members of the RNase A superfamily and are fragments of the 3' end of mature tRNAs (with CCA at the 3' end); the cleavage usually occurs between A/U and A/U near the 3'-end of the tRNAs \[[@B19-ncrna-03-00002],[@B30-ncrna-03-00002],[@B31-ncrna-03-00002]\]. i-tRFs are enriched within the internal regions of mature tRNAs, and they usually straddle the anticodon and begin right after the second or downstream nucleotide of the 5'-ends of tRNAs \[[@B32-ncrna-03-00002]\]. Recently, a previously undescribed 5' leader-exon tRNA fragment type was discovered to be associated with the loss of spinal motor neurons in CLP1-kinase dead mice \[[@B30-ncrna-03-00002],[@B33-ncrna-03-00002]\]. These fragments straddle the 5' leader sequence of pre-tRNAs and the 5' end of mature tRNAs. The mechanism of the tRF regulation of gene expression remains elusive. tRFs were shown to associate with Argonautes similar to siRNAs and miRNAs and were thus assumed to silence gene expression \[[@B31-ncrna-03-00002],[@B34-ncrna-03-00002]\]. It has also been shown that the displacement of pro-oncogenic transcripts with tRFs from the RNA-binding protein YBX1 might account for the suppression of human breast cancer progression by the tRFs \[[@B18-ncrna-03-00002]\]. In addition, the tRNA 3' external transcribed spacers might be excised and function as a sponge to reduce noise in transcription \[[@B35-ncrna-03-00002]\]. [Figure 1](#ncrna-03-00002-f001){ref-type="fig"} shows the general pathways for tDR biogenesis.

The functions of tDRs are not well understood. It was found that tDRs are correlated to the differentiation, development and metabolism of primitive eukaryotes \[[@B36-ncrna-03-00002],[@B37-ncrna-03-00002]\]. In the mouse, the mature sperm enrichment of tDRs was discovered, and the tDRs were thought to act as epigenetic factors or as regulators of endogenous retro-elements prior to implantation of the embryo \[[@B10-ncrna-03-00002],[@B38-ncrna-03-00002],[@B39-ncrna-03-00002]\]. In humans, tDRs have been found in several human cancer cell lines, but their correlation to tumorigenesis and progression remains elusive \[[@B16-ncrna-03-00002],[@B17-ncrna-03-00002],[@B18-ncrna-03-00002],[@B19-ncrna-03-00002],[@B40-ncrna-03-00002],[@B41-ncrna-03-00002],[@B42-ncrna-03-00002]\]. Compared with those in animals, the tDRs in plants are less investigated. tDRs were found to accumulate in the roots of *Arabidopsis thaliana* or in the shoots of barley during phosphate deprivation \[[@B43-ncrna-03-00002],[@B44-ncrna-03-00002]\]. A more recent study revealed the existence of conserved tDRs in *Arabidopsis thaliana*, *Oryza sativa* and *Physcomitrella patens* \[[@B45-ncrna-03-00002]\].

3. Identifying tDRs and Managing tDR Data {#sec3-ncrna-03-00002}
=========================================

Research on tDRs requires tools that facilitate the identification or retrieval of information on tRFs. In general, studies on tDRs could be classified into three categories: identifying the tDRs;analyzing tDR functions;storing or managing and manipulating data.

Computational approaches aimed at assisting researchers with these steps arose, and the following is a general review of the tools and databases for tDRs.

3.1. Identifying tDRs {#sec3dot1-ncrna-03-00002}
---------------------

In this review, three types of computational solutions to tDR identification will be summarized: general tools not specific to tDR identification in early studies, the command-line pipelines designed for tDR identification, and the integrated web server tRF2Cancer with user-friendly interfaces.

The main goal of small RNA deep-sequencing data analysis is to find the source types of RNAs and quantify their expression. Therefore, the mapping of reads is an important step. Early studies used BLAST \[[@B16-ncrna-03-00002],[@B19-ncrna-03-00002],[@B37-ncrna-03-00002],[@B46-ncrna-03-00002],[@B47-ncrna-03-00002]\], bowtie/bowtie2 \[[@B48-ncrna-03-00002],[@B49-ncrna-03-00002]\], exonerate \[[@B40-ncrna-03-00002]\], and the self-made string matching alignment algorithm to map small RNAs from the NGS data and identify tDRs from them \[[@B50-ncrna-03-00002]\].

Recent studies began to raise concerns regarding the subtleties of mapping to the genome versus to the tRNA alone. These concerns arose from the proposal of two different strategies to detect tDRs in 2015: the strategy proposed by Telonis et al., and the tDRmapper developed by Selitsky and Sethupathy. Telonis et al. proposed to identify candidate tRNA-fragment reads by mapping them to the genome, whereas the tDRmapper maps the trimmed reads directly to tRNAs \[[@B32-ncrna-03-00002],[@B50-ncrna-03-00002]\]. Telonis et al. mapped the reads to the whole genome and sought those reads with exact matches only to the tRNA sequences. In particular, they allowed for only exact matches in mapping. They claimed that with the limited lengths of tDRs and the sequence similarities among copies of tRNAs of the same anticodon, and even of different anticodons specifying the same amino acids, the allowance for mismatches might possibly confound the origins of tDRs. With regard to the requirements of exact matches, the three nucleotides immediately downstream of the 3' ends of tRNAs are replaced by CCA prior to mapping, to reserve CCA-trinucleotide-tail containing reads. Additionally, they permitted multiple hits on genomic tRNAs and retained the reads spanning exon--exon junctions but not those stepping partially on the introns. In their study, they identified a fourth class of tRFs, i-tRFs, and encouraged scepticism to the rationality of mapping the reads to the tRNA space alone in tRF identification. However, this study did not provide off-the-shelf software \[[@B32-ncrna-03-00002]\]. Almost at the same time, Selitsky and Sethupathy released tDRmapper, a command-line tool for the identification, naming and quantification of tDRs \[[@B50-ncrna-03-00002]\]. Of particular note is that tDRmapper adopted an "error type" hierarchical alignment scheme to handle possible mismatches attributed to chemical modifications. In each step, tDRmapper takes the reads that were unmapped in the last step as inputs. The inputs are then aligned with pre-tRNAs or tRNAs with some defined requirements, such as exact matches with mature or pre-tRNAs, as one to two mismatches or one to three base pair deletions with mature tRNAs. The resulting mappable reads in each step are collected, annotated and quantified as candidate tRFs.

The striking difference between the strategy of Telonis et al. and tDRmapper is whether or not the reads are mapped to the reference genome. In tDRmapper, the incomplete annotations of tRNA genes in the genome and the computational capacity are mentioned as reasons for not mapping to the genome. Specifically, reads mappable to both tRNAs and other regions in the genome are possibly indicative of new unannotated tRNA loci but are not reads derived from genomic templates other than tRNAs \[[@B50-ncrna-03-00002]\]. In contrast, Telonis et al. proposed that, due to tRNA lookalikes of nuclear and mitochondrial tRNAs and partial tRNA sequences, the reads mappable both to tRNAs and other known non-tRNA sequences should be excluded because their origins are dubious. Accounting for the number of loci in the genome with lengths and sequences similar to known tRNAs, the mapping to tRNAs alone would generate higher false positives and exaggerate the expression of certain tRFs from given tRNAs \[[@B32-ncrna-03-00002],[@B50-ncrna-03-00002]\]. Thus, all these controversies can be reduced to the balance between obtaining false positive and false negative results \[[@B51-ncrna-03-00002]\]. tDRmapper aimed at identifying more potential tRFs at the cost of increased false positives, whereas the Telonis study aimed at providing more accurate tRFs and excluded reads that were unlikely to derive from tRNAs.

To strike a balance between the total inclusion and total exclusion of dubious reads, we recently designed tRF2Cancer, an integrated web server for identifying tRFs from small RNA sequencing data and evaluating their expression in cancers \[[@B48-ncrna-03-00002]\]. tRF2Cancer consists of tRFfinder (tRF identification from small RNA deep-sequencing reads), tRFinCancer (inspect expression of tRFs across cancer types) and tRFBrowser (origins and chemical modifications of tRFs). Prior to mapping, tRFfinder maps the processed reads to the human genome and human transcript sequences to remove exogenous reads and reads other than tRFs (such as mRNAs, miRNAs, snoRNAs, snRNAs, rRNAs and repeats). This step helps to reduce the false positive results derived from non-tRF reads. tRFfinder then maps the reads to tRNA sequences to reduce false negative results. To evaluate the enrichment of reads on tRNAs after mapping, a binomial test was introduced. Although mismatches and indels are allowed in mapping by making use of bowtie/bowtie2, tRFfinder is cautious, and a scoring scheme was introduced. In this scheme, reads with mismatches or indels are given lower scores than those with exact matches, and mismatches resulting from chemical modifications are thus distinguished by way of differing scores. tRFfinder is the first web-based, user-friendly tool for the identification of tRFs. It strikes a balance between the total inclusion and total exclusion of dubious reads by giving reads of sceptical origins a lower score. tRFfinder is designed specifically for identifying human tRFs and their expression in multiple types of cancers. At the current stage, it only provides the web-based version for researchers to upload their sequencing data to the server; the command-line version is under development. [Table 1](#ncrna-03-00002-t001){ref-type="table"} shows the comparison between the work of Telonis et al., tDRmapper and tRFfinder.

To conclude, identifying tRFs from random degradation will remain a challenge. In addition to probability-based methods for evaluating the enrichment of reads on the genome or tRNAs, machine-learning algorithms might prove promising. In microRNA identification, machine-learning-based methods have been adopted to identify microRNAs based on known sequences and structural properties \[[@B52-ncrna-03-00002]\]. In addition, the lengths or cleavage site preferences are features that might be used in machine-learning-based methods to identify tDRs.

3.2. Databases of tDRs {#sec3dot2-ncrna-03-00002}
----------------------

Databases of tRFs help researchers obtain tRF sequences and evaluate expression counts in multiple experiments \[[@B47-ncrna-03-00002]\]. However, only a limited number of tRF databases are available in the field. In this review, four databases are introduced: tRFdb, tRFinCancer (in the tRF2Cancer), MINTbase, and the Olvedy et al. repertoire of prostate cancer.

tRFdb is a relational database of tRFs and other tRNA-related RNA fragments \[[@B47-ncrna-03-00002]\]. tRFdb contains tRF records from eight species ranging from bacteria to human. The database provides a uniform nomenclature and unique tRF ID for the tRFs. tRFdb provides information on tRF (original organisms, type, source tRNAs, sequence) and samples that contain the corresponding tRF reads, with interfaces to the GEO (Gene Expression Omnibus) and SRA (Sequence Read Archive) database. In addition, tRFdb displays the distribution of reads on tRNA sequences. To construct the database, tRFdb mapped the reads from the GEO/SRA database to the tRNA sequences, and the reads that were enriched in the tRNA sequences were further mapped to the whole genomes to exclude those reads mappable to outside tRNAs. The database contains tRF records from eight species, and therefore, it is suitable for research on tRF evolution or comparisons among species. However, the database contains only records of tRF-5s, tRF-3s, tRF-1s; it contains no records of i-tRFs or other tDRs. Furthermore, all the records in the database are results of bioinformatic prediction and require further experimental validation.

tRFinCancer is a database for viewing the expression of tRFs in multiple cancer types \[[@B48-ncrna-03-00002]\]. In tRFinCancer, the tRFs are predicted from TCGA (The Cancer Genome Atlas) data that contain the small RNA deep-sequencing data of 32 human cancer types and subtypes. The tRFs are identified using the tRFfinder. One feature of tRFinCancer is that users can determine the expression of tRFs in 32 cancer types; through comparisons of the expression in multiple cancers, researchers might be able to spot correlations between cancers and tRF expression levels. We hope that tRFinCancer can provide a starting point for functional studies of tRFs and their correlation with cancers.

tRFs can be generated from both nuclear tRNAs as well as mitochondrial tRNAs \[[@B53-ncrna-03-00002]\]. MINTbase is a database for tRFs of mitochondrial and nuclear origin \[[@B54-ncrna-03-00002]\]. In MINTbase, users can access five types of tDRs: tRF-5s, tRF-3s, i-tRFs, 5'-halves and 3'-halves of mitochondrial and nuclear origin. Different from the probability-based search methods used by tRFdb, MINTbase adopted the deterministic and exhaustive approach to search for all possible tRF candidates and retain those fragments mappable exclusively to tRNAs. In MINTbase, two methods are provided to users to view tRFs. Users can select and view tRFs according to tRF types, precursor tRNAs, and the precursor tRNA anticodon. Users can also search tRFs by tRNA names, fragment sequence, and by fragment label (defined by MINTbase). In addition to ordinary information on tRFs (i.e., sequence information, expression information, parental tRNA information and genomic information), based on the results page returned by MINTbase, users can view tRFs by five so-termed "vistas": genomic loci, RNA molecule, tRNA alignment, expression and summary. The two most striking features of MINTbase are that (1) it provides all-inclusive information on exhaustive tRF species of nuclear or mitochondrial origin and that (2) it provides interfaces for the submission of new tRF records. The ability to submit new records is important for updating a database. Currently, all the tRF records in MINTbase are produced from bioinformatic prediction and need to be validated by experiments in the future.

Olvedy et al. designed a repertoire of tRFs that focused exclusively on prostate cancer \[[@B55-ncrna-03-00002]\]. In the study, they examined and identified differentially expressed tRFs and their compositions in clinical prostate cancer samples representing different stages of the cancer. They also quantified the expression of tRFs across samples. The study provides a comprehensive catalogue (termed "database") of tRFs in different stages of prostate cancer; however, it does not provide a user-friendly interface.

As mentioned, tRFdb and MINTbase contain almost all tDR records in a given species, but do not provide a more focused view of tDRs in certain diseases. tRFinCancer offers options to view the expression of a given tDR across cancer types, which makes comparisons among cancers convenient; however, it does not provide a general overview of all tDRs in a given disease. The Olvedy et al. repertoire, however, is helpful for users to view the expression of tDRs in a given disease, namely prostate cancer. Therefore, the Olvedy et al. repertoire complemented by tRFinCancer might be helpful to researchers in that they offer a comprehensive view of tDR expression and their correlation to diseases. A comparison between the databases is shown in [Table 2](#ncrna-03-00002-t002){ref-type="table"}.

4. Perspectives {#sec4-ncrna-03-00002}
===============

tDRs are experiencing intense research, and their biological functions are gradually being revealed. Currently, off-the-shelf computational tools for identifying these small RNAs and databases to manage their information are available. However, as an integrated field of tDRs, many other areas of study are in need of tools for the analysis of tDRs. Three notable fields are the prediction of targets of tDRs, the study of their correlation to diseases, and the study of circulating tDRs. Currently, there are no tools for target prediction of tDRs. In retrospect, CLIP-Seq (cross-linking and Argonaute immunoprecipitation coupled with high-throughput sequencing) can be used to search for microRNA targets utilizing the microRNA:mRNA interaction mediated by Argonaute (AGO) proteins \[[@B56-ncrna-03-00002],[@B57-ncrna-03-00002],[@B58-ncrna-03-00002]\], and databases for these data are present (for instance, starBase \[[@B59-ncrna-03-00002],[@B60-ncrna-03-00002]\]). Similar techniques have been applied to study tDR:RNA interactions; for instance, meta-analysis of data generated by PAR-CLIP (photoactivatable-ribonucleoside-enhanced crosslinking and immunoprecipitation), CLASH (crosslinking, ligation, and sequencing of hybrids) and HITS-CLIP (high-throughput sequencing of RNA isolated by crosslinking immunoprecipitation, also referred to as CLIP-Seq) revealed the tRF association preferences for AGOs and mRNAs \[[@B46-ncrna-03-00002],[@B61-ncrna-03-00002]\]. These are promising methods to unravel the interactive dynamics between tDRs and their target proteins or RNAs. Tools to analyze and manage these data can facilitate the exploration of tDR biological functions by providing information on the targets of tDRs.

Insufficient tools are in place for the study of the correlations between tDRs and diseases. In retrospect, there are two dimensions in the study of correlations between tDRs and some given diseases. The first dimension highlights that given a sample from a disease of interest, the expression of different tDRs in this sample is detected to assess the up- or down-regulation of tDRs and to determine their expression patterns \[[@B16-ncrna-03-00002],[@B19-ncrna-03-00002],[@B40-ncrna-03-00002],[@B41-ncrna-03-00002],[@B42-ncrna-03-00002]\]. This dimension gives the overall patterns of tDR expression in the disease and offers some indications on the interactive dynamics between tDRs. This dimension of study requires pipelines and databases that focus on the disease under study, and Olvedy et al.'s repertoire is one example of this type of database \[[@B55-ncrna-03-00002]\]. The raw deep-sequencing data and analysis results provided by the tDR studies in different diseases, and the use of bioinformatic pipelines to predict tDRs from small RNA deep-sequencing data from samples of different diseases, are resources to build this type of database. The second dimension highlights the cross-comparison of tDR expression profiles in different types of diseases that can be used to study whether up- or down-regulation of the given tDRs is common to all related diseases or is unique to one specific case. This dimension indicates the potential of tDRs as diagnostic biomarkers in disease detection. One example of this type of database is tRFinCancer, which enables users to compare the expression of the tDR of interest in multiple cancers \[[@B48-ncrna-03-00002]\]. The first dimension lacks databases or computational pipelines that focus on the diseases under study, and the second dimension requires more inclusive databases. More work is required to tailor the pipelines or databases on the tDR for adequate study of diseases.

Accumulating evidence suggests the presence of circulating, functional tDRs in mouse serum \[[@B62-ncrna-03-00002],[@B63-ncrna-03-00002]\], dairy cows \[[@B63-ncrna-03-00002],[@B64-ncrna-03-00002]\], and humans \[[@B25-ncrna-03-00002],[@B63-ncrna-03-00002],[@B65-ncrna-03-00002]\]. The functions of circulating tDRs are not well characterized, and their potential as diagnostic biomarkers remains to be elucidated. In view of this, the databases to collect tDRs from circulating small RNA fragments from normal or disease samples, by bioinformatic prediction or collection of results from previous studies, might be helpful to the study of circulating tDRs.

In addition to new requirements from novel fields of study, several problems in the recent development of pipelines and databases remain. To systematically study tDRs and facilitate communication in the literature, it is important to establish a standard nomenclature for tDRs. However, the nomenclatures of tDRs are inconsistent among the different tools and different databases \[[@B48-ncrna-03-00002],[@B50-ncrna-03-00002],[@B53-ncrna-03-00002]\]. The difficulties of establishing a standardized tRF nomenclature lie in that only a small fraction of tDRs are validated by experiments. In addition, the origin of tDRs cannot be deterministically traced to one particular precursor tRNA due to tRNA isotypes; some common sequence motifs are shared among tRNAs with different anticodons coding for the same amino acid, and even allowing for one mismatch/insertion/deletion would probably confound the origin of tDRs. Thus, before establishing a uniform nomenclature for tDR, more research is needed to identify methods to trace tDRs back to their tRNA precursors.

Chemical modifications on tRNAs affect the RT-PCR amplification of tDRs and thus the false positive rates of tools in the field. Extensive chemical modifications of the small RNAs would abort the reverse transcription in RT-PCR and thus generate truncated reads whose 3' ends overlap exactly with these sites \[[@B66-ncrna-03-00002],[@B67-ncrna-03-00002]\]. Additionally, reverse transcriptase might pause at the chemically modified sites, which would enhance the likelihood of inserting the wrong nucleotides at these sites. Therefore, chemical modifications of the tRNAs and the corresponding tDRs might lead to increased truncated reads and higher chances of mismatch. However, recent computational tools to identify tDRs rarely take into account the effect of chemical modifications. To reduce the effect of truncated reads on identification, in tRFfinder we discarded the prediction results of tDRs whose 3' ends overlap with the chemically modified sites \[[@B48-ncrna-03-00002]\]. It is more difficult to address the problem of mismatch from chemical modifications. tRFfinder introduces the scoring matrix to distinguish the sources of mismatches. If the mismatches occur at the sites of chemical modification, 0.5 point per site is subtracted from the total score, and 1 point per site otherwise \[[@B48-ncrna-03-00002]\].

Telonis et al. prevented mismatch from mapping reads to the genome, indicating that even one mismatch might confound the origin of tDRs \[[@B32-ncrna-03-00002],[@B50-ncrna-03-00002]\]. This might introduce high false negative rates, since mismatches resulting from chemical modifications prevent the true tDR reads from mapping. However, tDRmapper allowed mismatches according to a hierarchical alignment scheme, which might confound mismatches of different origins. To address this contradiction, mismatches of different origins should be set apart, and in tRFfinder, a scoring scheme could help \[[@B48-ncrna-03-00002]\]. There are also new sequencing methods to handle the effect of chemical modifications. For instance, the AlkB-facilitated RNA methylation sequencing (ARM-Seq) method treats the samples with de-alkylating enzymes to remove methylations from tRNAs before RT-PCR \[[@B66-ncrna-03-00002]\]. This way, the effect of chemical modifications can be eliminated at the beginning, and RT-PCR can provide more accurate reads representative of small RNAs.

Nowadays, computational tDR tools mainly focus on identification and databases. The introduction of more reliable computational and statistical methods, or novel methods based on machine learning, is desired to accurately identify tDRs from small RNA sequencing data. Besides, more specialized databases are also expected to satisfy the diverse requirements of the researchers. In addition, new fields of study on tDRs are growing, while the tools are lacking in these fields. So the development of novel computational methods for tDR research will be a challenging but fruitful endeavour.
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![Biogenesis of tRNA-derived small RNAs (tDRs). In eukaryotic cells, precursor tRNAs undergo processing and become mature tRNAs. The cleavage of precursor tRNAs generates tRNA-derived small RNA fragments (tRF-1s) and 5' leader-exon tRFs. tRF-5s, tRF-3s, i-tRFs, 5' halves and 3' halves are generated by the cleavage of mature tRNAs.](ncrna-03-00002-g001){#ncrna-03-00002-f001}

ncrna-03-00002-t001_Table 1

###### 

List of tools specific to RNA-derived small RNA (tDR) identification.

  Name                                                              Mapping to                                             Potential Effects                    Mapping Tools         Mismatches, Indels, and Chemical Modification                                 tDR Types Detectable                   User Interface
  ----------------------------------------------------------------- ------------------------------------------------------ ------------------------------------ --------------------- ----------------------------------------------------------------------------- -------------------------------------- --------------------------------
  Telonis et al., \[[@B32-ncrna-03-00002],[@B50-ncrna-03-00002]\]   Genome to exclude reads mappable outside tRNAs         Potential false negative             --                    Mismatches/indels not allowed                                                 All four tRF types                     No packaged pipelines provided
  tDRmapper                                                         tRNAs alone                                            Potential false positive             Built-in algorithms   Error type hierarchy                                                          Multiple tRFs and tRNA halves          Command line
  tRFfinder                                                         First to genome and known transcripts, then to tRNAs   Moderate false positive & negative   bowtie/bowtie2        Allowed (with options), but given different weights (scores) in result page   Multiple tDR including all tRF types   Website interface

ncrna-03-00002-t002_Table 2

###### 

List of databases of tDRs.

  Name                       Records                                                  Methods                                                                                                   Species                 User Interface
  -------------------------- -------------------------------------------------------- --------------------------------------------------------------------------------------------------------- ----------------------- --------------------------------------------------
  tRFdb                      tRF-3s, -5s, -1s from nucleus                            Bioinformatic prediction                                                                                  Eight species           A website to search and view tRFs
  tRFinCancer                All four types from nucleus across cancer types          Bioinformatic prediction                                                                                  32 human cancer types   A website to view tRFs expression across cancers
  MINTbase                   All types from mature, nuclear and mitochondrial tRNAs   Bioinformatic prediction                                                                                  Human                   Website to search and view tRFs
  Olvedy et al. repertoire   All types in prostate cancer                             Bioinformatic prediction, with qPCR quantification to validate differential expression of selected tRFs   Human prostate cancer   A catalogue
